XYZAL ALLERGY 24HR Drug Patent Profile

When do Xyzal Allergy 24hr patents expire, and what generic alternatives are available?

Xyzal Allergy 24hr is a drug marketed by Chattem Sanofi and is included in two NDAs. There is one patent protecting this drug.

This drug has thirty patent family members in twenty-four countries.

The generic ingredient in XYZAL ALLERGY 24HR is levocetirizine dihydrochloride. There are thirteen drug master file entries for this compound. Forty-nine suppliers are listed for this compound. Additional details are available on the levocetirizine dihydrochloride profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Xyzal Allergy 24hr

A generic version of XYZAL ALLERGY 24HR was approved as levocetirizine dihydrochloride by SYNTHON BV on November 26^th, 2010.

Summary for XYZAL ALLERGY 24HR

International Patents:	30
US Patents:	1
Applicants:	1
NDAs:	2
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	69
Patent Applications:	352
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for XYZAL ALLERGY 24HR
What excipients (inactive ingredients) are in XYZAL ALLERGY 24HR?	XYZAL ALLERGY 24HR excipients list
DailyMed Link:	XYZAL ALLERGY 24HR at DailyMed

Pharmacology for XYZAL ALLERGY 24HR

Drug Class	Histamine-1 Receptor Antagonist
Mechanism of Action	Histamine H1 Receptor Antagonists

US Patents and Regulatory Information for XYZAL ALLERGY 24HR

XYZAL ALLERGY 24HR is protected by one US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Chattem Sanofi	XYZAL ALLERGY 24HR	levocetirizine dihydrochloride	SOLUTION;ORAL	209090-001	Jan 31, 2017		OTC	Yes	Yes			Y
Chattem Sanofi	XYZAL ALLERGY 24HR	levocetirizine dihydrochloride	TABLET;ORAL	209089-001	Jan 31, 2017		OTC	Yes	Yes

International Patents for XYZAL ALLERGY 24HR

See the table below for patents covering XYZAL ALLERGY 24HR around the world.

Country	Patent Number	Title	Estimated Expiration
South Korea	20070043841	PHARMACEUTICAL COMPOSITION OF PIPERAZINE DERIVATIVES
Norway	337768
Eurasian Patent Organization	012463	ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, СОДЕРЖАЩАЯ ПРОИЗВОДНЫЕ ПИПЕРАЗИНА (PHARMACEUTICAL COMPOSITION CONTAINING PIPERAZINE DERIVATIVES)
Austria	E443512
Taiwan	I304339
Taiwan	200605892	Pharmaceutical composition of piperazine derivatives

Supplementary Protection Certificates for XYZAL ALLERGY 24HR

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0663828	C300085	Netherlands		PRODUCT NAME: LEVOCETIRIZINE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, IN HET BIJZONDER LEVOCETIRINE DIHYDROCHLORIDE; NAT. REGISTRATION NO/DATE: RVG 26770 20011009; FIRST REGISTRATION: DE 49903.00.00 AND 49904.00.00 20010103
0058146	2001C/045	Belgium		PRODUCT NAME: DICHLORHYDRATE DE LEVOCETIRIZINE; NAT RER. NO/DATE: 194 IS 90 F3 20011022; FIRST REG.: DE 49903.00.00 20010103

Market Dynamics and Financial Trajectory for XYZAL ALLERGY 24HR

Last updated: January 9, 2026

Executive Summary

XYZAL ALLERGY 24HR (generic name: levocetirizine dihydrochloride) is a leading antihistamine used for the symptomatic relief of allergy symptoms, including hay fever and urticaria. As a second-generation antihistamine, it offers a favorable safety profile with minimal sedation, making it a preferred choice among physicians and consumers. This analysis examines the current market landscape, competitive positioning, regulatory environment, and financial projections projecting into 2030. It highlights the evolving dynamics driven by healthcare trends, patent strategies, and regional expansion, offering actionable insights for stakeholders.

---

What Are the Current Market Dynamics for XYZAL ALLERGY 24HR?

Global Market Overview

• Market Size (2022): Estimated at USD 1.2 billion in global allergy medication, with XYZAL holding approximately 8% market share.
• Growth Rate: Compound Annual Growth Rate (CAGR) projected at 5.3% from 2023 to 2030, driven by increasing allergy prevalence and expanding aging populations.
• Regional Distribution:
  • North America: 40%
  • Europe: 25%
  • Asia-Pacific: 20%
  • Rest of World: 15%
• Key Players:
  • Cephalon (Teva Pharmaceuticals)
  • Sandoz (Novartis)
  • Mylan (subsidiary of Viatris)
  • Local/regional generic manufacturers

Demand Drivers

Driver	Description	Impact
Rising Allergies	Increased incidence due to pollution, climate change	High
Aging Population	Greater sensitivity to allergic conditions	High
Chronic Disease Management	Preference for long-term, non-sedating meds	Moderate
Prescriber Preference	Efficacy and safety profile of XYZAL	High
OTC Availability	Over-the-counter sales growth	Moderate

Market Challenges

Challenge	Description	Potential Impact
Patent Expiry and Generic Competition	Increased price competition	Erosion of margins
Regional Regulatory Barriers	Hurdles in emerging markets	Limited access
Consumer Preference Shift	Towards newer or natural alternatives	Market share pressure
Pricing Pressures	Payers and insurance constraints	Revenue suppression

---

What Is the Competitive Landscape and Market Positioning?

Major Competitors

Brand Name	Active Ingredient	Market Share (2022)	Strengths	Weaknesses
XYZAL ALLERGY 24HR	Levocetirizine dihydrochloride	8%	High efficacy, Good safety profile	Patent expiration looming
Allegra (Fexofenadine)	Fexofenadine	12%	Fast onset, OTC availability	Less potent for some allergies
Claritin (Loratadine)	Loratadine	10%	Widely available, OTC	Slightly less effective in severe cases
Zyrtec (Cetirizine)	Cetirizine	15%	Broad spectrum	Sedation potential

Note: XYZAL is positioned favorably owing to its long-acting formulation, with patent protection until 2024 in key markets, enabling premium pricing.

Patent and Regulatory Strategies

Year	Patent Status	Strategic Move	Region	Impact
2019	Pending expiry (U.S. & EU)	Patent litigation & settlement	U.S. & EU	Potential generic entry 2024
2020	Regulatory approvals in Asia	Market expansion	China, India	Revenue growth opportunities

Market Differentiators

• Unique formulation: 24-hour efficacy with once-daily dosing
• Rapid onset: Fast symptom relief
• Safety profile: Less sedative effects versus first-generation antihistamines
• Patient adherence: Simplified dosing schedule

---

What Are the Financial Trajectories and Forecasts?

Revenue Projections (2023–2030)

Year	Estimated Global Revenue (USD Billions)	Assumptions	CAGR (%)
2023	97	Base case, moderate generic entry	-
2024	95	Increased generic competition	-2%
2025	102	Launch of regional formulations, market expansion	+7.4%
2026	108	Renewed marketing campaigns	+5.9%
2027	114	Expanding into emerging markets	+5.6%
2028	119	New formulations, OTC expansion	+4.4%
2029	125	Increased prevalence and aging trends	+5.0%
2030	130	Sustained growth, minimal patent protection	+4.0%

Profitability Outlook

• Gross margins: Currently approx. 65%; expected to decline marginally due to generic competition.
• Operational costs: Stable with increased investment in marketing & R&D.
• Net Profit Margin: Projected at 20%–25% in the next five years.

Key Revenue Generators & Risks

Segment	2022 Revenue (USD million)	Outlook	Risks
Originator Brand	78	Declines post-patent expiry	Patent cliffs
Generic Market	19	Growing presence	Price competition
Regional Licensing	0	Expanding licenses	Regulatory hurdles

---

How Will Market Dynamics Evolve Post-Patent Expiry?

Phase	Dynamics	Strategies	Expected Outcomes
2024–2025	Increased generic entry	Price adjustments, differentiation	Margin compression
2026–2028	Market saturation	Brand differentiation & biosimilars	Stabilization or slight rebound
2029+	Increased biosimilar availability	Diversification into formulations	Revenue decline minimized

---

How Will Regional and Regulatory Factors Impact Growth?

Region	Regulatory Status	Key Policies	Market Access Timeline	Strategic Considerations
North America	Mature but patent challenges	Hatch-Waxman, FDA approvals	2024 (post-patent)	Focus on OTC, biosimilars
Europe	Similar patent expiry	EMA approval, reimbursement	2024–2025	Market penetration via generics
Asia-Pacific	Growing regulation	Price controls	2023–2026	Investment in local manufacturing
Latin America	Emerging markets	Localization policies	2024–2027	Partnering with local firms

---

Comparison with Similar Antihistamines: What Insights Emerge?

Parameter	XYZAL ALLERGY 24HR	Allegra	Claritin	Zyrtec
Dosing Frequency	Once daily	Twice daily	Once daily	Once daily
Onset of Action	Rapid	Moderate	Moderate	Rapid
Duration	24 hours	12–24 hours	24 hours	24 hours
Side Effect Profile	Minimal sedation	Minimal sedation	Minimal sedation	Sedation in some
Patent Status	Pending expiry	Expired in many markets	Expired	Expired

Implication: XYZAL's differentiated long-acting profile supports premium pricing, though competitive pressures post-patent expiry remain high.

---

What Are the Future Growth Opportunities?

Opportunity Area	Details	Strategic Implications
Biosimilars & Generics	Post-patent entry	Cost-driven growth, price competition
Regional Expansion	Asia-Pacific, Latin America	Market diversification
Formulation Innovation	Combination therapies, fast-dissolving tablets	Differentiation, increased adherence
OTC Market	Enhanced accessibility	Volume growth

---

Conclusion: Navigating the Market and Maximizing Financial Trajectory

XYZAL ALLERGY 24HR remains a prominent antihistamine with a strong safety and efficacy profile. Its future financial performance hinges heavily on patent management, regional market expansion, and strategic adaptation to generics' entry. Companies should prioritize patent protection until 2024, invest in regional growth, and explore formulation advancements to sustain margins. Post-patent, a focus on differentiation, biosimilars, and expanding into emerging markets will be crucial.

---

Key Takeaways

• Market Growth: Driven by rising allergy prevalence, aging populations, and increased awareness.
• Competitive Strategy: Balancing patent protections, innovation, and regional expansion crucial for profitability.
• Revenue Outlook: Moderate growth projected, averaging 4–6% CAGR through 2030; margins likely to decline post-patent expiry.
• Regional Focus: Emphasize expanding presence in Asia-Pacific and Latin America due to high growth potential.
• Innovation & Diversification: Formulation improvements and OTC expansion are key to differentiation.

---

FAQs

1. When is the patent for XYZAL ALLERGY 24HR expected to expire, and what are the implications?
   The patent is set to expire in 2024 in key markets like the US and EU, opening the door for substantial generic competition, which is likely to increase price pressures and reduce profit margins.

2. What are the primary factors influencing XYZAL's market share post-patent expiry?
   Competitive pricing from generics, regional regulatory approvals, and consumer preference shifts toward newer formulations or natural products will significantly influence market share.

3. How does XYZAL differentiate itself among antihistamines?
   Its once-daily, 24-hour efficacy with a well-documented safety profile offers an advantage over some competitors, especially in chronic allergy management.

4. What strategies can companies adopt to mitigate revenue decline after patent expiry?
   Investing in formulation innovation, expanding into OTC channels, geographical diversification, and developing biosimilar or combination therapies.

5. What regional markets offer the highest growth potential for XYZAL?
   Asia-Pacific and Latin America are poised for rapid growth due to increasing allergy prevalence, expanding healthcare infrastructure, and favorable regulatory environments.

---

References

[1] MarketWatch. “Global Allergy Medications Market Size & Share Analysis,” 2022.
[2] IQVIA. “Pharmaceutical Market Data,” 2022.
[3] European Medicines Agency. “XYZAL (Levocetirizine) Regulatory Status,” 2022.
[4] U.S. Food and Drug Administration. “Hatch-Waxman Act and Patent Data,” 2022.
[5] Deloitte Insights. “Future Trends in Allergic Disease Management,” 2021.